Long-Term Durability of Percutaneous Tibial Nerve Stimulation for the Treatment of Overactive Bladder

Journal of Urology

Volumn 183, Issue 1, 2010, Pages 234-240

  MacDiarmid, Scott A ^a   Peters, Kenneth M ^b   Shobeiri, S Abbas ^d   Wooldridge, Leslie S ^c   Rovner, Eric S ^e   Leong, Fah Che ^f   Siegel, Steven W ^g   Tate, Susan B ^h   Feagins, Brian A ⁱ  

^a Alliance Urology Specialists   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c MERCY HEALTH PARTNERS   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f SAINT LOUIS UNIVERSITY   (United States)

^g Metro Urology   (United States)

^h UNIVERSITY OF LOUISVILLE   (United States)

ⁱ Dallas Center for Pelvic Medicine   (United States)

Author keywords

electric stimulation therapy; nocturia; overactive; tibial nerve; urge; urinary bladder; urinary incontinence

Indexed keywords

TOLTERODINE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE SEVERITY; ELECTROSTIMULATION; HUMAN; MICTURITION; NERVE STIMULATION; NOCTURIA; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PERCUTANEOUS TIBIAL NERVE STIMULATION; PRIORITY JOURNAL; RISK ASSESSMENT; STRUCTURED QUESTIONNAIRE; TIBIAL NERVE; TREATMENT DURATION; URGE INCONTINENCE; URINE INCONTINENCE;

ELECTRIC STIMULATION THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; TIBIAL NERVE; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 71249126479     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.08.160     Document Type: Article

References (27)

1. ICS (International Continence Society) Factsheet 2-Overactive Bladder, 2005. http://www.icsoffice.org/ASPNET_Membership/Membership/Documents/DocumentsDownload.aspx?DocumentID=284 Accessed May 2009
2. Stewart W.F., Van Rooyen J.B., Cundiff G.W., et al. Prevalence and burden of overactive bladder in the United States. World J Urol 20 (2003) 327
3. Nitti V.W. The prevalence of urinary incontinence. Rev Urol 3 (2001) S2
4. Dmochowski R.R., and Newman D.K. Impact of overactive bladder on women in the United States: results of a national survey. Curr Med Res Opin 23 (2007) 65
5. Pelletier E.M., Vats V., and Clemens Q. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder. Am J Manag Care 15 (2009) S108
6. Starkmarn J.S., Wolter C.E., Scarpero H.M., et al. Management of refractory urinary urge incontinence following urogynecological surgery with sacral neuromodulation. Neurourol Urodyn 26 (2007) 29
7. Zinkgraf K., Quinn A.O., Ketterhagen D., et al. Percutaneous tibial nerve stimulation for treatment of overactive bladder and urinary retention in an elderly population. Urol Nurs 29 (2009) 30
8. Govier F.E., Litwiller S., Nitti V., et al. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of multicenter study. J Urol 165 (2001) 1193
9. Klingler H.C., Pycha A., Schmidbauer J., et al. Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study. Urology 56 (2000) 766
10. Vandoninck V., van Balken M.R., Finazzi-Agro E., et al. Percutaneous tibial nerve stimulation in the treatment of overactive bladder: urodynamic data. Neurourol Urodyn 22 (2003) 227
11. van Balken M.R., Vandoninck V., Gisolf K., et al. Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction. J Urol 166 (2001) 914
12. Peters K.M., MacDiarmid S.A., Wooldridge L.S., et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the Overactive Bladder Innovative Therapy (OrBIT) Trial. J Urol 182 (2009) 1055
13. Peters K.M., Killinger K.A., Ibrahim I.A., et al. The relationship between subjective and objective assessments of sacral neuromodulation effectiveness in patients with urgency-frequency. Neurourol Urodyn 27 (2008) 775
14. Sand P and Zinner N: What is urgency? Examining the clinical adequacy of the ICS definition of urgency. Presented at the 2005 ICS Conference, Montreal, Canada, abstract 56.
15. Coyne K.S., Matza L.S., and Thompson C.L. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 14 (2005) 849
16. Leng W.W., and Chancellor M.B. How sacral nerve stimulation neuromodulation works. Urol Clin North Am 32 (2005) 11
17. van der Pal F., Heesakkers J.P., and Bemelmans B.L. Current opinion on the working mechanisms of neuromodulation in the treatment of lower urinary tract dysfunction. Curr Opin Urol 16 (2006) 261
18. Brazzelli M., Murray A., and Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol 175 (2006) 835
19. Flynn M.K., Amundsen C.L., Perevich M.A., et al. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 191 (2009) 2608
20. Pfizer. Detrol® LA Instructions for Use (2006)
21. Nitti V.W., Dmochowski R., Sand P.K., et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 178 (2007) 2488
22. Zinner N., Gittelman M., Harris R., et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 171 (2004) 2311
23. MacDiarmid S.A., and Staskin D.R. Percutaneous tibial nerve stimulation (PTNS): a literature-based assessment. Curr Blad Dys Rep 4 (2009) 29
24. Kohli N., and Rosenblatt P.L. Neuromodulation techniques for the treatment of the overactive bladder. Clin Obstet Gynecol 45 (2002) 218
25. Amundsen C.L., Romero A.A., Jamison M.G., et al. Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure?. Urology 66 (2005) 746
26. Wooldridge L.S. Percutaneous tibial nerve stimulation for the treatment of urinary frequency, urinary urgency and urge incontinence: results from a community-based clinic. Urol Nurs 29 (2009) 177
27. Peters K., Carrico D., and Burks F. Validation of a sham for percutaneous tibial nerve stimulation. Neurourol Urodyn 28 (2009) 58